Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Grant revenue by Year
Grant revenue — Total (BARDA, DARPA, CEPI & Gates Foundation) ($M) ($M)
Moderna Grant revenue: $22M in FY2025, down 40.5% from a year earlier.
Latest, FY2025
22
Period ended Dec 31, 2025
Change on a year earlier
-40.5%
37 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Operations & Note 3.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Grant revenue — Total (BARDA, DARPA, CEPI & Gates Foundation) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 22 | -40.5% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 37 | -60.6% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 94 | -75.8% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 388 | -47.2% | Form 10-K (filed 2025-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 735 | +38.9% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 529 | +4,308.3% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 12 | -4.8% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 12.6 | -56.4% | Form 10-K (filed 2021-02-26) ↗ |
| FY2017 | Dec 31, 2017 | 28.9 | +318.8% | Form 10-K (filed 2019-03-13) ↗ |
| FY2016 | Dec 31, 2016 | 6.90 | – | Form 10-K (filed 2019-03-13) ↗ |
Breakdown
What makes up grant revenue
Cite this data
StockData. (2026). Moderna Grant revenue ($M), annual FY2016–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rev-grant
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.